Release of cardiac troponin-T following successful percutaneous transluminal coronary angioplasty

Berkten BERKALP, Derviş ORAL, İsfendiyar CANDAN, Ahmet ALPMAN, Kenan ÖMÜRLÜ, Gülgün PAMİR, Çetin EROL, Celal KERVANCIÖGLU, Güneş AKGÜN, Yahya LALELİ, Turhan AKYOL

Dept. of Cardiology, Medical School of Ankara University, Ankara, TURKEY

Cardiac troponin T (cTn-T) measurements were studied in 34 patients who underwent successful percutaneous transluminal coronary angioplasty (PTCA) for defining myocardial damage during procedure. Blood samples were drawn before and between 7 and 14 h (mean of 10 h) following PTCA. Before PTCA, high cTn-T levels were found in 8 of 14 patients with stable and 15 of 20 patients with unstable angina pectoris. None of the patients had significant increases in cTn-T after uncomplicated PTCA (1.0±1.9 ng/ml; 2.2±5.2 ng/ml, p<0.05). In conclusion, successful PTCA does not cause myocardial damage irrespective of clinical stability. [Turk J Med Res 1994; 12(5): 222-223]

Key Words: Coronary angioplasty, Troponin T, Angina pectoris

Percutaneous transluminal coronary angioplasty (PTCA) is established as a common technique for myocardial revascularization. There is a controversy whether PTCA causes myocardial damage or not (1-3). Up to 20% of patients who undergo this procedure have mild elevations in creatine phosphokinase-MB (1,2,4). It is traditionally used to identify myocardial injury in clinical practice. Myoglobin is also an early and sensitive indicator of myocardial damage but not specific (5). Recently some studies suggested cardiac troponin T (c-Tn T) which had different amino acid sequence of protein in skeletal muscle, was sensitive and specific for myocardial injury (6-11).

In this study, using cTn-T, myocardial injury was evaluated during successful PTCA.

MATERIALS AND METHODS
The study population consisted of 34 patients (27 men and 7 women, median age years; range 34 to 70) who were undergoing elective PTCA for stable (in 14 patients) or unstable (in 20 patients) angina pectoris. Of all patients, 12 had myocardial infarction at least 2 months ago.

Coronary angioplasty was made by Judkins technique from right femoral artery. Before angioplasty procedure, a standard drug treatment (diltiazem 90-180 mg and aspirin 300 mg, daily) was instituted within 48 hours. Patients were fully heparinized during procedure. A total of 41 stenosis were subjected to PTCA. Fifteen patients had stenosis in the left anterior descending coronary artery, 5 in the left circumflex artery, 7 in the right coronary artery, 3 in the left anterior descending and right coronary arteries, 2 in the left anterior descending and circumflex and 2 in the left circumflex and right coronary arteries.

The degree of stenotic lesions was between 80% and 100%. The angioplasty balloon was inflated at 6 to 8 atmosphere. An average inflation duration was 60-90 ms and the average two inflations were used in each lesions. There were not any complications during procedure. After balloon deflation no patient complained of chest pain or had ST segment-T wave changes on electrocardiography or signs of a new myocardial infarction. Residual stenosis were below 30%. All patients had successful PTCA.

Blood samples were withdrawn before and between 7 and 14 h (mean of 10 h) following the angioplasty procedure. cTn-T concentrations were measured by the enzyme immunoassay (Boehringer Mannheim, Germany). The upper limit of cTn-T was accepted 0.5 ng/ml in normal healthy group.

Statistics
All data was reported as mean±SD. Student's t test and Chi-Square test were used to test differences between variables.

RESULTS
A total of 41 stenosis in 34 patients was successfully dilated by PTCA. In all patients, cTn-T concentrations showed in significant changes after PTCA. The results were given in Table 1. cTn-T measurements were above 0.5 ng/ml in 8 (57%) patients with stable angina pectoris, but 15 (75%) with unstable angina pectoris (p>0.05). In comparison of stable and unstable angina groups, the mean values of cTn-T were not statistically different before and after procedure (p>0.05; p>0.05).

DISCUSSION
In the last several decades, serum levels of cardiac enzymes and isoenzymes have become the final arbiters...
CARDIAC TROPOGIN-T FOLLOWING CORONARY ANGIOPLASTY

Table 1. cTn-T measurements before and after PTCA

<table>
<thead>
<tr>
<th>PTCA</th>
<th>cTn-T ng/ml</th>
<th>before</th>
<th>after</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stable angina n=14</td>
<td>0.6±0.3</td>
<td>2.5±6.7</td>
<td>&gt;0.05</td>
<td></td>
</tr>
<tr>
<td>Unstable angina n=20</td>
<td>1.2±2.5</td>
<td>2.0±3.9</td>
<td>&gt;0.05</td>
<td></td>
</tr>
<tr>
<td>Total n=34</td>
<td>1.0±1.9</td>
<td>2.2±5.2</td>
<td>&gt;0.05</td>
<td></td>
</tr>
</tbody>
</table>

by which myocardial damage is diagnosed or excluded. Because conventionally used enzymes are neither perfectly sensitive nor specific, there is need for a new sensitive and cardiосpecific marker of myocardial damage (7). cTn-T measurements are highly sensitive and specific in diagnosis of myocardial injury (6-15).

PTCA is widely used to dilate stenosis of coronary arteries. After PTCA, it is a sensitive marker for determining whether myocardial injury is present or not. In uncomplicated PTCA patients, Tn-T does not increase in serum (16). But angiographically visible occlusion of smaller side branches, although not accompanied by ST segment changes or chest pain, leads to an increase in cTn-T above normal range. Reocclusion of a successfully dilated stenosis causes a marked rise in cTn-T. The extent of myocardial damage after PTCA can be estimated by cTn-T measurement (16). In another study, troponin measurement was applied to detect myocardial injury during PTCA and it was found that uncomplicated PTCA did not cause significant rise in Tn-T levels (17).

Both of these studies consisted of patients with stable and unstable angina pectoris, and no significant myocardial damage was seen as a result of successful PTCA irrespective of the stability of the coronary artery disease (16,17). There is also some studies that clinically and angiographically successful PTCA can cause the elevation of cTn-T, indicating myocardial damage (2,4).

Our result suggested uncomplicated PTCA was not associated with myocardial injury as they were confirmed by others (16,17). Before PTCA, the high cTn-T concentrations in stable and unstable angina pectoris were interesting finding. It is known up to 50% of patients with unstable angina have increased cTn-T concentrations (9,10,13,15) and it may be a useful prognostic myocardial necrosis (7,10). Because of its release kinetics the early and late diagnosis of myocardial damage can be made by this measurement (6,7,18). In our knowledge, the high cTn-T serum levels have not been shown in stable angina pectoris. The cumulative effects of recurrent brief ischemic attacks may be responsible from micro and patchy myocardial damage (19). Additionally, stable angina pectoris is a clinical diagnosis and asymptomatic, silent ischemia may be effective an increased cTn-T measurements. M is suggested that biochemical marker release may or may not reflect irreversible ischemia (4,9).

A gradual release of Hypoxylic enzymes from reversibly injured myocardial cells was showed after short periods of coronary occlusion without myocardial necrosis (20).

In conclusion, increased cTn-T in serum can identify a subgroup of ischemic heart disease patients who have serious p'ronosis and may consider revascularization as soon as possible. If PTCA is applied successfully, no myocardial damage is occurred irrespective of clinical stability.

REFERENCES